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toxicity are needed to achieve remission in many first-treatedRemission, relapse, and re-remission of proliferative lupus ne-
patients and in most patients treated for a second time. Thephritis treated with cyclophosphamide.
Background. Long-term intravenous cyclophosphamide optimal management of patients with identified adverse pre-
(IVC) in combination with corticosteroids is standard therapy dictors of response needs further study.
for proliferative lupus nephritis, but it has limitations. There
are few data on long-term remission rates, predictors of relapse,
and the ability to achieve a second remission with currently
recommended IVC regimens. Nephritis is one of the most important causes of mor-
Methods. A cohort of 85 patients with proliferative lupus
bidity and mortality in patients with systemic lupus ery-glomerulonephritis (focal N 5 33, diffuse N 5 52) treated with
thematosus (SLE) [1]. The most popular therapeutic reg-IVC was assembled in three institutions. Timing and predictors
of remission, relapse, and re-remission were evaluated with imen, particularly for proliferative glomerulonephritis,
Kaplan–Meier analyses and Cox models. consists of long-term pulses of intravenous cyclophos-
Results. The median time to remission was 10 months,
phamide (IVC) [2–6] in combination with corticoste-whereas an estimated 22% of patients had not remitted after
2 years. The median time to relapse among 63 patients who roids. This regimen has been shown to be effective in
had achieved remission was 79 months. In multivariate models, both observational studies and randomized trials, and
adverse predictors of remission were a delay in the initiation most patients respond initially to this regimen. However,of therapy from the time nephritis was clinically diagnosed
some investigators have also drawn attention to the limi-[hazard ratio (HR) 0.58, P 5 0.063] and a higher amount of
proteinuria (HR 0.86 per 1 g/24 hours, P 5 0.014). Predictors tations of IVC, including toxicity during long-term use
of earlier relapse for patients entering remission included a [7] and the possibility of relapses [8, 9]. The optimal
longer time to remission (HR 1.029 per month, P 5 0.025), a
duration of therapy that would minimize relapses with-history of central nervous system involvement (HR 8.41, P 5
out substantially increasing toxicity is not known. More0.002), and World Health Organization histology (P 5 0.01).
Among the 23 patients who relapsed during follow-up, the importantly, there is little evidence on how soon patients
median time to re-remission was 32 months, and with three who relapse may enter into remission for a second time.
exceptions, all patients took substantially longer time to remit
Although there are several reports on predictors of long-the second time compared with their first remission (P 5 0.01).
term outcomes [including end-stage renal diseaseThe time to re-remission was longer in patients who had taken
longer to remit the first time (HR 0.979 per month, P 5 0.16), (ESRD) and death] [10–13], there is inadequate knowl-
in patients who had relapsed earlier after the first remission edge about predictors of relapse and the ability to(HR 1.071 per month, P 5 0.002), and in those with evidence
achieve a second remission among patients with prolifer-of chronicity in the original kidney biopsy (P 5 0.015).
Conclusions. Prolonged courses with a cumulative risk of ative nephritis treated with currently recommended IVC
regimens. Such information would be important to ob-
tain because it would offer some guidance on what a
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clinician could expect in trying to establish a secondphamide.
remission in patients who have relapsed after IVC ther-
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METHODS tis, serositis, central nervous system (CNS) disease (in-
cluding psychosis, seizures, paresis or paralysis, and cra-Study cohort
nial nerve involvement), autoimmune hemolytic anemiaAll patients with biopsy-documented diagnosis of pro-
(defined as hemoglobin below 12 g/dL and reticulo-liferative lupus nephritis (World Health Organization
cytosis along with positive Coombs test), other anemiatypes III or IV [14]) treated with IVC at the Department
(defined as hemoglobin below 12 g/dL without hemoly-of Pathophysiology, University of Athens, the affiliated
sis), leukopenia (defined as ,3000 leukocytes per cubicEugenidion Hospital, and the University Hospital of the
millimeter), and thrombocytopenia (defined as plateletUniversity of Ioannina School of Medicine until Decem-
count ,100,000 per cubic millimeter) separately at anyber 1998 were included in this analysis. Additional de-
point up until the clinical diagnosis of nephritis and spe-tailed information on patients who had started IVC else-
cifically at the time of the diagnosis of nephritis; hyper-where before their first visit was obtained from medical
tension, low C4 or C3 complement levels, amount ofrecords.
proteinuria, creatinine level and creatinine clearance atThe typical regimen used in the study cohort was pred-
the time of diagnosis of lupus nephritis; activity andnisone (0.5 mg/kg daily) for four weeks, with gradual
chronicity index in the renal biopsy [11]; prior therapytapering to the minimum dose required for control of
including per os cyclophosphamide, azathioprine, pulseextrarenal manifestations and intravenous infusions of
corticosteroids, corticosteroids at daily doses exceedingcyclophosphamide (0.75 to 1.0 g/m2) monthly for up to
the equivalent of 30 mg methylprednisolone; and delaysix months and then once every two months for 12
for initiation of IVC from the time nephritis was diag-months and then every three months for another 18
nosed clinically and from the time the renal biopsy wasmonths. Continuation of treatment beyond the three
years was up to the physician’s discretion. Upon signs performed. The same variables were also considered as
of relapse or deterioration, monthly administration of potential predictors of the time to relapse (for patients
IVC was reintroduced. Deviations from this regimen who did remit) and of the time from relapse to second
could be due to patient preferences, toxicity, and non- remission (for patients who relapsed), with the exception
compliance. that for the latter analysis, we considered variables such
as creatinine, proteinuria, complement levels, and hyper-
Definitions tension at the time of the relapse. For the time-to-relapse
Clinical evidence of nephritis required the presence of analysis, we also considered the time it took to reach
proteinuria ($0.5 g/24 hours) or an active urine sediment remission as a potential predictor. For the time-to-sec-
(.8 to 10 erythrocytes per high power field; or casts). ond remission analysis, we also considered the time it
The diagnosis was documented by biopsy (light micros- took to reach remission the first time and the time it
copy and immunofluorescence). Lupus nephritis was took to relapse after the first remission as a potential
classified by the World Health Organization classifica- predictor.
tion criteria [14].
Remission was defined by the presence of all of the Statistical analysis
four following criteria in at least two determinations one Time to event analyses were performed according to
month apart: (a) absence of active urine sediment, (b)
the Kaplan–Meier method, and comparisons involved
proteinuria of non-nephrotic range (,3 g/24 hours), (c)
the log-rank test [15]. Predictive modeling was per-a reduction by at least 30% in the level of proteinuria,
formed with Cox proportional hazards models [16]. Mul-and (d) stable or improving creatinine clearance, an im-
tivariate models used a step-wise backward eliminationprovement of creatinine clearance by at least 30% if the
procedure based on a likelihood ratio test with P . 0.10baseline creatinine was $2.5 mg/dL or stable creatinine
for removal and P , 0.05 for entry of variables. To avoidclearance if the baseline creatinine was ,2.5 mg/dL.
using too many variables given the limited number ofRelapse was defined as the presence of any of the
events and observations, in the initial multivariate mod-following criteria in at least two determinations: (a) in-
els, we considered only the six variables with lowest Pcrease in proteinuria by more than 2 g/24 hours, (b)
values in univariate analyses (generally P , 0.15) in theactive urine sediment, or (c) increase in creatinine by
modeling of time to remission and time to relapse and.30%.
the three variables with the lowest P values in univariate
Database analyses (generally P , 0.25) in the modeling of time
to re-remission. Clinical site was not a significant predictorThe following data were collected and considered as
in any of the models, and site-adjusted estimates werepredictors of the time to remission: age at the time of
similar (data not reported). Analyses were conducted inSLE onset and age at the time of diagnosis of nephritis;
sex; the presence of mucocutaneous involvement, arthri- Advanced SPSS [17]. All P values are two-tailed.
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Table 1. Characteristics of the patient population Thirty-four patients stopped IVC before completing the
typical three-year regimen. Of those, 24 stopped beforeAge at SLE onset, mean (sd) years 28.7 (14.3)
Age at nephritis onset, mean (sd) years 32.9 (14.7) completing at least two years of treatment, and 15
Creatinine at time of IVC initiation, mean (sd) mg/dL 1.3 (0.8) stopped even before completing one year. The reasonsProteinuria at time of IVC initiation, 2.2 (2.0)
for these early discontinuations were rapid progressionmean (sd) g/24 hours
Low complement at time of IVC initiation 59/80 to irreversible kidney damage (N 5 4), poor response
Hypertension at time of IVC initiation 36/82 with a decision to change to oral cyclophosphamide andChronicity index on renal biopsy, mean (sd) 3.0 (2.5)
azathioprine (N 5 1), peripheral neuropathy (N 5 1),Activity index on renal biopsy, mean (sd) 7.5 (3.6)
Number of patients with other abnormalities at onset recurrent infections in the setting of neutropenia (N 5
(at any other time) 1), patient decision in the setting of good response (N 5CNS disease 6 (17)
4), and erratic follow-up (N 5 4).Serositis 12 (18)
Arthritis 31 (61)
Mucocutaneous involvement 53 (64) Time to remission
Leukopenia 16 (24)
Two patients had to use a different regimen (cyclo-Autoimmune hemolytic anemia 8 (11)
Other anemia 48 (50) sporine 3 mg/kg per day and azathioprine in combination
Thrombocytopenia 5 (11) with oral cyclophosphamide 1 mg/kg per day of each,Prior therapy for SLE and complications
respectively) to achieve remission. As shown in FigureOral cyclophosphamide 13
Azathioprine 23 1A, the vast majority of patients seemed to enter remis-
Pulse corticosteroids 6 sion eventually, but some patients may take a long time.Corticosteroids .30 mg/day MPE 37
The median time to remission was 10 months. The esti-Patients switching to other regimens to achieve first
remission 2 mated proportions entering into remission at 6 months,
Abbreviations are: CNS, central nervous system; IVC, intravenous cyclophos- 12 months, and 2 years were 33, 58, and 78%, respec-
phamide; MPE, methylprednisone equivalent; SLE, systemic lupus erythema- tively. Table 2 shows the important predictors of thetosus.
time to remission in univariate and multivariate Cox
models. Remission took longer to reach in patients who
had delayed the onset of IVC for more than three monthsRESULTS
after clinical diagnosis, were younger at the time SLE
Patient population and nephritis were diagnosed, and had more pronounced
A total of 85 patients (69 female and 16 male) with proteinuria. There was also a suggestion that patients
proliferative lupus nephritis were included in the analy- whose nephritis was accompanied by autoimmune hemo-
sis. Thirty-three patients had focal proliferative nephritis lytic anemia took longer to remit. In the multivariate
(type III), and 52 had diffuse proliferative nephritis (type regression, the most important independent predictors
IV). Eight patients reached ESRD during follow-up, and were the level of proteinuria and a delay of more than
two of them died; four more patients died from other three months from the clinical diagnosis. The rate of
causes. All patients with ESRD and four of six patients remission was almost half among patients who had de-
who died had type IV glomerulonephritis. Other charac- layed therapy for more than three months and decreased
teristics of the patient population are shown in Table by 14% for each increase of 1 g/24 hours in the level of
1. Sixty-three of the 85 patients entered into remission proteinuria. Of note, even though patients with histo-
during follow-up. Of those, 23 had relapsed during fol- logic type IV were modestly slower to remit (hazard
low-up, and 15 of them had already entered into a second
ratio 0.80), this finding was not statistically significantremission at the time data were censored for analysis.
(P 5 0.4). Nevertheless, at 50 months, all patients withFifteen patients started IVC more than two months after
type III histology were expected to have entered remis-having a renal biopsy, and 30 patients had delayed the
sion, as compared with only 81.8% of patients with grouponset of IVC therapy for more than three months from
IV histology.the time kidney disease was clinically detected for the
first time. In the majority of cases in which therapy was Time to relapse
delayed, the delay was due to the time it took for primary
The median time to relapse was 79 months from thecare physicians to document the diagnosis and refer the
time of remission. In Kaplan–Meier analysis (Fig. 1B),patient for treatment or hesitation by the patient to start
the risk of relapse seemed to slightly decrease over time;therapy. The median time from clinical detection to onset
that is, patients who had stayed in remission for longerof IVC was two months (interquartile range 1 to 8
had a lesser risk of relapsing in the immediate future.months).
Table 3 shows the important predictors of relapse for
Treatment experience patients who had entered into remission. In both univari-
ate and multivariate analyses, the coexistence of CNSThe median duration of treatment in our cohort was
31 months. Forty-six of the 85 patients had stopped IVC. disease at the time of the diagnosis of nephritis and the
Fig. 1. Kaplan–Meier curves for (A) the time
to remission after the start of intravenous cy-
clophosphamide (IVC; N 5 85), (B) the time
to relapse after remission (N 5 63 with remis-
sion), and (C ) the time to re-remission after
relapse (N 5 23 with relapse). Each patient
censored without an event is shown by a cross
in the Kaplan–Meier curves. The number of
patients at risk and the cumulative number of
events at 0, 20, 40, 60, 80, and 100 months are
also shown under each Kaplan–Meier plot.
Ioannidis et al: IVC in lupus nephritis262
Table 4. Predictors of second remissionTable 2. Predictors of remission
Hazard ratio (P value) Hazard ratio (P value)
Predictor Univariate Multivariate Predictor Univariate Multivariate
Time to relapse from first remissionDelay .3 months from
clinical diagnosis 0.56 (0.046) 0.58 (0.063) per month 1.053 (0.004) 1.071 (0.002)
Chronicity index 5 0 20.5 (0.033) 56.2 (0.015)Proteinuria per 1 g/24 hours 0.85 (0.024) 0.86 (0.014)
Age at nephritis onset per year 1.0145 (0.090) NS Time to first remission per month 0.981 (0.223) 0.979 (0.160)
Age at SLE onset per year 1.0182 (0.046) NS A hazard ratio ,1 denotes a longer time to second remission.
AHA at nephritis onset 0.44 (0.082) NS
Activity index per point 0.936 (0.121) NS
Abbreviations are: NS, not selected in the multivariate model; SLE, systemic
lupus erythematosus; AHA, autoimmune hemolytic anemia. A hazard ratio ,1
Patients not entering a second remission after three yearsdenotes a longer time to remission.
were very unlikely to ever remit.
Among the 15 patients who entered a second remis-
sion, the time to re-remission was longer on average than
Table 3. Predictors of relapse the time that these same patients had taken to enter
Hazard ratio (P value) remission originally (median 15 months vs. 5 months);
12 out of 15 took longer to enter remission the secondPredictor Univariate Multivariate
time than it had taken to enter remission the first time.CNS disease at nephritis onset 3.61 (0.025) 8.41 (0.002)
Time to remission per month 1.017 (0.145) 1.029 (0.025) Of the remaining eight patients who had not yet entered
WHO type IV 0.47 (0.080) 0.28 (0.01) a second remission, six had already been followed for a
Delay .2 months from biopsy 2.10 (0.120) NS
longer time after their relapse than it had taken for theCreatinine when IVC started
per 1 g/dL 1.38 (0.120) NS first remission (P 5 0.01).
History of leukopenia 2.31 (0.062) NS Table 4 shows the important predictors of second re-
Abbreviations are: CNS, central nervous system; IVC, intravenous cyclophos- mission among patients who had relapsed. In both uni-
phamide; NS, not selected in the multivariate model; SLE, systemic lupus erythe-
variate and multivariate analyses, the time to re-remis-matosus. A hazard ratio ,1 denotes a longer time to relapse.
sion was longer if the relapse had occurred earlier after
the first remission and was probably also more prolonged
if the time it had taken to enter into remission the first
time that it had originally taken to reach remission were time was longer. Patients with no chronic damage in the
predictive of relapse. Patients with group IV histology original kidney biopsy were more likely to enter again
seemed to take longer on average to relapse, if they into remission. The time to re-remission was not signifi-
reached remission. There was a suggestion that patients cantly associated with the creatinine level, level of pro-
teinuria, or the presence of hypertension or hypocom-who had delayed IVC initiation after biopsy documenta-
plementemia at the time of relapse.tion, those with a higher level of creatinine and those
with a history of leukopenia were more likely to relapse,
but none of these predictive factors remained significant DISCUSSION
in the multivariate analysis. Of note, the risk of relapse
In this study, we analyzed the timing and predictors ofamong patients who entered into remission was not sta-
remission, relapse, and second remission of proliferativetistically significantly associated with the delay in initia-
glomerulonephritis in SLE patients treated with long-
tion of therapy from the time of clinical documentation
term IVC. In concordance with previously published ex-
(P 5 0.74), a high activity index (P 5 0.66), a high perience [1, 18], we observed that most patients enter
chronicity index (P 5 0.84), or the patient’s age at SLE into remission with IVC therapy. However, many pa-
or nephritis onset (P 5 0.74 and 0.95, respectively). tients may take very long to remit. Moreover, relapse
was very common in our study cohort. On average, pa-Time to re-remission
tients on IVC seemed to gain a little more than six years
Fifteen of the 23 patients who relapsed entered into (median 79 months) of remission. The rate of relapses
a second remission during follow-up. Of the 23 patients, seemed to decrease the longer patients stayed in remis-
15 used IVC alone. One patient used both IVC and sion. Relapses occurred earlier in patients with evidence
intravenous immunoglobulin, and one patient used both of severe SLE such as CNS disease and in patients who
IVC and azathioprine. Two patients used oral cyclophos- had taken longer to remit. Finally, achieving a second
phamide 2 mg/kg per day, and 4 patients used azathio- remission in patients who had relapsed was far more
prine. As shown in Figure 1C, the median time from difficult than achieving remission the first time. Re-
relapse to re-remission was 32 months. The probability remission was less likely to occur among patients who
had taken longer to remit the first time and those whoof entering re-remission gradually decreased over time.
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had relapsed sooner after achieving remission the first retrospective character of most studies in this field, in-
cluding the present report. Criteria of remission based ontime. The probability of a second remission diminished
over time and seemed to become negligible three years proteinuria and creatinine clearance are less satisfactory
than criteria incorporating an inactive urine sediment.after the relapse.
Several studies have assessed predictors of long-term Definitions of relapse are even more difficult to validate,
as there is even more limited comparative evidence. Foroutcomes, especially end-stage renal disease in patients
with SLE glomerulonephritis [1]. These predictors in- example, simple changes in creatinine may not necessar-
ily reflect lupus-related activity in the kidneys. Neverthe-clude an elevated creatinine, nephrotic-range protein-
uria, low levels of complement, severe anemia, hyperten- less, all relapses in our cohort were also associated with
an active urine sediment. There is a need for developingsion, diffuse proliferation on kidney biopsy, a high
activity and chronicity index, male gender, black race, uniformly accepted criteria for defining remission and
relapse in the short term and validating these criteria onyoung age, and low socioeconomic status [1]. These fac-
tors may also be important for long-term outcomes in long-term hard outcomes [20]. Prospective, preferably
randomized, studies of an adequately large sample sizethe context of currently recommended long-term IVC
regimens, although most previous studies collected data would be needed to overcome the biases stemming from
variability in the therapeutic management of patientson patients with various histologic types and various
treatment modalities, including short-term courses of and accompanying selection biases [21]. Finally, although
retrospective in nature, our study had the advantage ofIVC. There are even more limited data on the predictors
of immediate responses to current long-term IVC regi- assembling the largest population of IVC-treated pa-
tients with proliferative nephritis in the literature, to ourmens and the propensity of proliferative glomerulone-
phritis to relapse and re-remit with IVC treatment. knowledge. Patients had a common racial background
and were recruited from three hospitals sharing a stan-One team of investigators reported that young age
and a higher chronicity and activity index, as well as a dardized therapeutic approach, which obviates strong
selection biases.delay in initiation of therapy, were associated with a
higher probability of relapse [19]. In our study, we ob- The median time of first remission in our study was
10 months. Although typically the response to IVC hasserved that a delay in initiation of therapy as well as
proteinuria and, in univariate associations at least, prob- been thought to be fairly swift, often occurring within 2
to 6 months, a previous study also reported that the meanably a higher activity index and younger age were pre-
dictors of slower remission rather than faster relapse. time to reach renal remission was 21 months, whereas the
number of IV CY pulses averaged to 10 (abstract; PandoNevertheless, the risk of relapse seemed to correlate
inversely with the time it took to remit. Some of the et al, Arthritis Rheum 37:S179, 1994). Many patients may
take a very long time to enter into remission. This trans-predictors of relapse that we observed, namely CNS dis-
ease and leukopenia, may be surrogates for the presence lates into a substantial cumulative dose of IVC that in-
creases the risk for serious subsequent toxicity. It is thusof more severe SLE disease. The reason why patients
with type IV glomerulonephritis seemed to have a lower very important to know which patients are then likely
to respond a second time, if they relapse. Our data sug-risk of relapsing once entering remission is not obvious.
The effect may be spurious. It may reflect the fact that gest that patients who relapse take on average 32 months
to re-remit. Apparently, some of them will never enterall eight patients who suffered irreversible renal damage
and four of six patients who died had type IV disease. remission again, especially those who took longer to
remit the first time and/or relapsed rapidly. With anThus, the remaining patients who did remit may have
been selected to have a seemingly more favorable prog- average treatment experience of 31 months during the
first remission and maintenance phase, two or more addi-nosis. Still, relapses are a serious problem for both type
III and type IV glomerulonephritis. One recent study tional years of IVC could create a substantial load of
cumulative toxicity. Based on our study results, we rec-reported that a one third of patients with proliferative
lupus nephritis relapsed at a median of 21 months after ommend that patients who have adverse prognostic fac-
tors for re-remission, such as difficult remission and earlyremission (abstract; Illei et al, Arthritis Rheum 41:S242,
1998). In other studies, rates of relapse have ranged from relapse, should be considered for treatment with alterna-
tive regimens.25% at 5 years and 46% at 10 years to 36% early after
discontinuation of therapy [8, 9, 19]. Our estimate (50% In fact, our study offers further evidence about the
limitations of IVC and the need for developing and eval-at 79 months) is based on one of the largest ICV-treated
cohort of proliferative nephritis in the literature and is uating alternative regimens. Fifteen of 85 patients in
our cohort stopped IVC before completing one year ofwell within this range.
Differences in associations and in rates of relapse in therapy, usually because of lack of efficacy, side effects,
and patient noncompliance, the latter often also re-various studies may be also dependent on the criteria
used to define relapse and remission as well as on the flecting toxicity concerns. A much larger number of pa-
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with systemic lupus erythematosus receiving intermittent pulsetients did not complete a three-year course. Candidate
cyclophosphamide. Ann Intern Med 119:366–369, 1993
alternative agents include azathioprine and intravenous 8. Moroni G, Quaglini S, MacCario M, Banfi G, Ponticelli C:
Nephritic flares are predictors of bad long-term outcome in lupusimmunoglobulin. Preliminary experience with azathio-
patients. Kidney Int 50:2047–2053, 1996prine is promising [22], but definitive data are lacking.
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